New LiverMultiScan mapping tool identifies NASH

Perspectum Diagnostics released details regarding the latest version of its LiverMultiScan magnetic resonance imaging technology which identified nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, according to a press release.

The latest version of LiverMultiScan will feature machine learning-based, automatic segmentation of cT1 and proton density fat fraction parametic maps of the liver parenchyma and be accessible on more field strengths across major scanner manufacturers.

According to data presented at The Liver Meeting 2018, Perspectum’s cT1 mapping was an effective biomarker for identifying NASH with significant fibrosis.

Additionally, PDFF and cT1 in combination performed well for stratification and increased the diagnostic utility of multiparametric MRI when used in conjunction with serum biomarkers of metabolic disease.

“We are pleased that the results of the studies being presented at The Liver Meeting continue to validate the prognostic capabilities of multiparametric MRI,” Stefan Neubauer, MD, chief medical officer of Perspectum Diagnostics, said in a press release. “With the ability to strongly predict clinical outcomes equal to that of liver biopsy, LiverMultiScan is an important, non-invasive diagnostic tool for characterizing liver disease and identifying early stages of [nonalcoholic fatty liver disease] and NASH.”

The new LiverMuliScan version will release in early 2019.

Reference: www.perspectum-diagnostics.com

Editor's note: This article has been updated with corrected information.

Perspectum Diagnostics released details regarding the latest version of its LiverMultiScan magnetic resonance imaging technology which identified nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, according to a press release.

The latest version of LiverMultiScan will feature machine learning-based, automatic segmentation of cT1 and proton density fat fraction parametic maps of the liver parenchyma and be accessible on more field strengths across major scanner manufacturers.

According to data presented at The Liver Meeting 2018, Perspectum’s cT1 mapping was an effective biomarker for identifying NASH with significant fibrosis.

Additionally, PDFF and cT1 in combination performed well for stratification and increased the diagnostic utility of multiparametric MRI when used in conjunction with serum biomarkers of metabolic disease.

“We are pleased that the results of the studies being presented at The Liver Meeting continue to validate the prognostic capabilities of multiparametric MRI,” Stefan Neubauer, MD, chief medical officer of Perspectum Diagnostics, said in a press release. “With the ability to strongly predict clinical outcomes equal to that of liver biopsy, LiverMultiScan is an important, non-invasive diagnostic tool for characterizing liver disease and identifying early stages of [nonalcoholic fatty liver disease] and NASH.”

The new LiverMuliScan version will release in early 2019.

Reference: www.perspectum-diagnostics.com

Editor's note: This article has been updated with corrected information.